Added 25 days ago Drug news

Analysis of phase III TWILIGHT trial for Brilinta showed reduced risk of bleeding in acute coronary syndromes.- AstraZeneca

New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that Brilinta (ticagrelor) monotherapy, from AstraZeneca, reduced the...

Added 26 days ago Drug news

FOURIER outcomes phase III study of Repatha shows effectiveness in myocardial infarction.- Amgen

Amgen announced a new analysis from the Repatha (evolocumab) cardiovascular outcomes (FOURIER) phase III study that evaluates the effectiveness of...

Added 4 months ago Drug news

European Commission approves marketing authorisation for Forxigato include positive cardiovascular (CV) outcomes and renal data from the Phase III DECLARE-TIMI 58 trial.

AstraZeneca announced that the European Commission has approved an update to the marketing authorisation for Forxiga (dapagliflozin) to include positive...

2018 ESC/EACTS Guidelines on myocardial revascularization

These Guidelines represent the third time that the ESC and EACTS have brought together cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body of evidence, with the mission of drafting balanced...

Added 5 years ago

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

The management of acute myocardial infarction continues to undergo major changes. Good practice should be based on sound evidence, derived from well-conducted clinical trials.

Added 7 years ago

Chest pain of recent onset: assessment and diagnosis

This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made.

Added 9 years ago

Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.

Background: The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was noninferior to...

Added 3 months ago

Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.

Background: Patients experiencing acute coronary syndromes (ACS) with high-risk features frequently undergo percutaneous coronary intervention (PCI) with stent placement, prompting the requisite administration of aspirin and...

Added 3 months ago

Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis.

Hemostasis requires both platelets and the coagulation system. At sites of vessel injury, bleeding is minimized by the formation of a hemostatic plug consisting of platelets and fibrin. The traditional view of the regulation of blood...

Added 3 months ago

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death...

Added 7 years ago

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients...

Added 2 years ago